Logo for LaunchBio Program: Investor ConnectLogo for LaunchBio Program: Investor Connect

Bridging the Gap Between Innovation and Capital

Boston, MA

Investor Connect Live in Boston



Calling all early stage Boston area companies!

Building on our successful monthly, invitation-only series, top level investors are connected with promising, early stage, life science entrepreneurs through a curated process and meet in a facilitated conversation. We are proud of the 51% of Investor Connect companies that have received further interest from investors.

This series is for life science founders and C-level executives who are raising funding (Pre-Seed, Seed, Series A, Series B) and interested in expanding their investor network.

If you are interested in participating in our first ever LIVE IN-PERSON Investor Connect event in Boston, please complete the Entrepreneur application by clicking the link here!



3:30 – 4:00 PM – Arrival & Registration

4:00 – 4:10 PM – Intros – LaunchBio, Prendio, SciShield

4:10 – 4:50 PM – Block 1 (8 x companies)

4:50 – 5:00 PM – Break

5:00 – 5:40 PM – Block 2  (8 x companies)

5:40 – 6:00 PM – General Q&A

6:00 – 7:00 PM – Networking & Reception


Applications will be selected based on meeting the following criteria:

Boston and surrounding areas.

Company type:
Companies in a broad range of modalities and therapeutic areas.

Areas of Interest:

Looking for pre-seed or seed stage companies focused on cardiovascular disease or high-potential seed- series A.

Qualifying start-ups can apply here today.


  • Kathryn Segien

    Kathryn Segien, MBA, Vice President, Hercules Capital

    Katie Segien is a Vice President at Hercules Capital focusing on business development and investments in emerging growth-stage life science and healthcare companies. Katie has been with Hercules for over 12 years and has previously worked at Boston Children’s Hospital in their Innovation & Digital Health Accelerator. She was a Flare Scholar at Flare Capital in Boston in 2018 and remains on their seed fund, Flare Scholar Ventures, providing pre-seed capital to healthcare-focused companies.

  • Sergine Brutus Sweeney HeadShot

    Sergine Brutus Sweeney, PhD, Venture Associate, Mass General Brigham Ventures

    Sergine Brutus Sweeney is a Venture Associate with Mass General Brigham Ventures focusing on new company creation. She is a translational scientist with a background in cell biology and biomarker development. Sergine previously led translational research programs at PathAI, where she oversaw AI-based histopathology biomarker development strategies for biopharma clients, with a focus on oncology. Sergine holds a BSc from Emory University and a PhD from Harvard University.

  • David Prim

    David Prim, PhD, Senior Associate, Broadview Ventures

    David Prim, PhD, is a Senior Associate at Broadview Ventures. David generally supports the Broadview investment team in its day-to-day operations, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company involvement. Prior to joining Broadview, David was a Senior Associate at Locust Walk, a global life sciences transaction firm, where he led engagements for biopharma and medtech clients guiding corporate development strategy and supporting sell-side, buy-side, and financing deal execution.